Sysmex Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hisashi Ietsugu
- Full Time Employees
- 10,861
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1-5-1, Wakinohama-Kaigandori Kobe HY Japan 651-0073
- IPO Date
- Nov 15, 1995
- Website
- sysmex.co.jp
- Similar Companies
- Business
- Sysmex Corporation (6869.T) develops, manufactures and markets diagnostic instruments, reagents and software for in vitro diagnostics, primarily in hematology, hemostasis, urinalysis, immunochemistry and clinical chemistry; it also provides solutions in life sciences, flow cytometry, digital pathology and integrated laboratory automation systems. The company offers flagship product lines such as the BioMajesty series of clinical chemistry analyzers, which support high-speed processing and multifunctionality for diverse laboratory needs, alongside hematology analyzers like the Sysmex XN-Series, urinalysis systems including the UF-Series, hemostasis instruments via alliances, and informatics software for workflow standardization. Sysmex operates globally across more than 190 countries and regions through subsidiaries including Sysmex Europe SE, Sysmex America Inc., Sysmex Asia Pacific Pte Ltd. and Sysmex Shanghai Ltd., serving clinical laboratories, healthcare providers and research institutions with a focus on advancing personalized medicine and novel treatments. Founded in 1968 as TOA Medical Electronics in Kobe, Japan, where it maintains global headquarters, Sysmex rebranded to its current name in 1998 and has grown into a top-10 global in vitro diagnostics leader, holding the number one market share in hematology, urinalysis sediment and hemostasis alliance fields. The company supports operations via 76 subsidiaries and one associated company as of recent reports, with sales and service extending to North America, Europe, Asia-Pacific, the Middle East, Africa, China, the United States, Germany, the United Kingdom and Singapore. Recent developments include a September 2025 agreement to acquire the medical equipment business of JEOL Ltd., encompassing clinical chemistry analyzers like the BioMajesty series, through a wholly owned subsidiary expected to close in April 2026; an expansion of its strategic alliance with CellaVision AB to advance hematology solutions including next-generation cell morphology analyzers; and a planned relocation of its global headquarters to a new facility in Kobe's Sannomiya district in spring 2028 to enhance synergies, innovation and sustainable growth ahead of its 60th anniversary. Sysmex also maintains long-standing partnerships such as with Kuehne+Nagel for healthcare logistics distribution in Europe and Siemens Healthineers for hemostasis products. These initiatives underscore Sysmex's strategy to broaden its portfolio, accelerate global expansion and strengthen operational foundations amid evolving healthcare demands.
Company News
Boston Scientific (NYSE:BSX) and Sysmex (OTCMKTS:SSMXY) Critical Survey
Sysmex (OTCMKTS:SSMXY) Sees Unusually-High Trading Volume – Here’s What Happened
Sysmex Corporation (SSMXY) Q1 2027 Earnings Call Prepared Remarks Transcript
Sysmex (OTCMKTS:SSMXY) Shares Gap Up After Strong Earnings
Alphatec (NASDAQ:ATEC) and Sysmex (OTCMKTS:SSMXY) Critical Survey
Thermo Fisher Scientific (NYSE:TMO) versus Sysmex (OTCMKTS:SSMXY) Head to Head Contrast
Sysmex (OTCMKTS:SSMXY) vs. DexCom (NASDAQ:DXCM) Head to Head Survey
Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Down 42.7% in February
Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Decreases By 53.9%
Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Increases By 601.3%
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors